| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (Constellation) CPI-0610-02 / MANIFEST study | A Phase 1/2 Study of CPI-0610, a Small Molecule Inhibitor of BET Proteins: Phase 1 (Dose Escalation of CPI-0610 in Patients with Hematological Malignancies) and Phase 2 (Dose Expansion of CPI-0610 with and without Ruxolitinib in Patients with Myelofibrosis) | Leber, Dr Brian | Open to recruitment | NCT02158858 |
| (GlycoMimetics) GMI-1271-301 | A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia | Khalaf, Dr Dina | Open to recruitment | NCT03616470 |
| (Horizon Health Network) The M4 Study | The Terry Fox Pan-Canadian Multiple Myeloma Molecular Monitoring Cohort Study (The M4 Study) | Kouroukis, Dr Tom | Open to recruitment | NCT03421132 |
| (McMaster) CTTC 1901 / OZM-099 | A Randomized Pilot Trial comparing Anti-Thymocyte Globulin (ATG) with ATG plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis against Acute and Chronic Graft Versus Host Disease (GVHD) in Matched Donor Hematopoietic Cell Transplants (HCT) | Walker, Dr Irwin | Open to recruitment | NCT04202835 |
| (Novartis) CCTL019B2302 | A Phase IIIb Study of the Safety and Efficacy of Tisagenlecleucel Out of Specification for Commercial Release in Patients Who Are Consistent With the Label Indication | Kouroukis, Dr Tom | Open to recruitment | NCT04094311 |
| (Sierra Oncology) SRA-MMB-301 / MOMENTUM | A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy | Hillis, Dr Christopher | Open to recruitment | NCT04173494 |
| (UHN) CFI-400945-CL-002 | An Open-Label, Dose Escalation, Safety and Pharmacokinetic Study of CFI-400945 Fumarate Administered Orally to Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | Leber, Dr Brian | Open to recruitment | NCT03187288 |
| CMRG 007 / MCRN 007 / ALGONQUIN | A Phase 1/2 Multi-Center, Open Label, Dose Escalation Study to Determine the Recommended Phase 2 Dose, Safety and Efficacy of the Antibody Drug Conjugate GSK2857916 in Combination with Pomalidomide and Low-Dose Dexamethasone in Subjects with Relapsed and/or Refractory Multiple Myeloma (MM) | Kouroukis, Dr Tom | Open to recruitment | NCT03715478 |
| (CCTG) LY.17 | A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma | Fraser, Dr Graeme | Recruitment on hold - COVID-19 | NCT02436707 |
| (Celgene) ACE-536-MDS-002 / COMMANDS | A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions | Leber, Dr Brian | Recruitment on hold - COVID-19 | NCT03682536 |
| (AbbVie) M16-191 | A Randomized, Open-Label, Phase 3 Study Of Navitoclax In Combination With Ruxolitinib Versus Ruxolitinib Alone In Subjects With Myelofibrosis | Leber, Dr Brian | Suspended/On hold | NCT04472598 |
| (AbbVie) M20-178 / TRANSFORM-2 | A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) | Leber, Dr Brian | Suspended/On hold | NCT04468984 |
Find a Trial
Contact Us